Literature DB >> 32456714

Are we repeating mistakes of the past? A review of the evidence for esketamine.

Mark A Horowitz1, Joanna Moncrieff1.   

Abstract

Esketamine has been licensed for 'treatment-resistant depression' in the USA, UK and Europe. Licensing trials did not establish efficacy: two trials were negative, one showed a statistically significant but clinically uncertain effect, and a flawed discontinuation trial was included, against Food and Drug Administration precedent. Safety signals - deaths, including suicides, and bladder damage - were minimised.

Entities:  

Keywords:  Esketamine; antidepressants; depression; ketamine; suicide

Mesh：

Substances：

Year:  2021        PMID： 32456714     DOI： 10.1192/bjp.2020.89

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  6 in total

1.  Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System.

Authors:  Haoning Guo; Bin Wang; Shuying Yuan; Silin Wu; Jing Liu; Miaoquan He; Jisheng Wang
Journal:  Front Pharmacol       Date:  2022-04-08       Impact factor: 5.988

2.  How to deprescribe esketamine in resistant depression? A point of view after first clinical uses.

Authors:  T Taillefer de Laportalière; A Yrondi; A Jullien; P Cestac; F Montastruc
Journal:  Epidemiol Psychiatr Sci       Date:  2022-01-11       Impact factor: 6.892

3.  The antidepressant effect and safety of non-intranasal esketamine: A systematic review.

Authors:  Sanne Y Smith-Apeldoorn; Maurice Vischjager; Jolien Ke Veraart; Jeanine Kamphuis; Marije Aan Het Rot; Robert A Schoevers
Journal:  J Psychopharmacol       Date:  2022-05-12       Impact factor: 4.562

4.  Later is not necessarily better: limitations of survival analysis in studies of long-term drug treatment of psychiatric conditions.

Authors:  Joanna Moncrieff; Janus Christian Jakobsen; Max Bachmann
Journal:  BMJ Evid Based Med       Date:  2021-09-23

Review 5.  The molecular pathophysiology of depression and the new therapeutics.

Authors:  Haihua Tian; Zhenyu Hu; Jia Xu; Chuang Wang
Journal:  MedComm (2020)       Date:  2022-07-21

6.  Decreased bone mineral density in ovariectomized mice is ameliorated after subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine.

Authors:  Yuko Fujita; Kenji Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2020-08-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.